Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02762877 · OUTCOME

Percentage of Participants With EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer · Source last updated 2020-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Time between patient tumor tissue biopsy and and blood collection (blood collected after the patient progressed on EGFR targeted therapy)

What was measured

Detection of EGFR T790M alterations in plasma using the OncotypeSEQ Liquid Select assay. Progression on EGFR targeting therapy (erlotinib, gefitinib, afatinib) assessed clinically or radiologically

Analysis population: Non-squamous NSCLC patients who progressed on erlotinib, gefitinib, or afatinib treatment and received mutation testing on both their plasma and tissue samples.

Groups in this outcome

Patients With Non-squamous NSCLC Who Are Progressing on Erloti

Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Patients With Non-squamous NSCLC Who Are Progressing on Erloti19

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Patients With Non-squamous NSCLC Who Are Progressing on Erloti32Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        32
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Detection of EGFR T790M alterations in plasma using the OncotypeSEQ Liquid Select assay. Progression on EGFR targeting therapy (erlotinib, gefitinib, afatinib) assessed clinically or radiologically
groups
  1. description
    Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
    id
    OG000
    title
    Patients With Non-squamous NSCLC Who Are Progressing on Erloti
param Type
NUMBER
population Description
Non-squamous NSCLC patients who progressed on erlotinib, gefitinib, or afatinib treatment and received mutation testing on both their plasma and tissue samples.
reporting Status
POSTED
time Frame
Time between patient tumor tissue biopsy and and blood collection (blood collected after the patient progressed on EGFR targeted therapy)
title
Percentage of Participants With EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice